EUSA Pharma ('EUSA'), a transatlantic specialty pharmaceutical companyfocused on oncology, pain control and critical care, today announced theappointment of Iain McGill to the role of President, Europe andInternational. The appointment marks the completion of the build of bothEUSA's executive management team and the company's commercial infrastructure.With EUSA now present in over 80 countries, with teams covering the US andover 20 European territories including the major EU markets, the companyanticipates achieving strong sales growth and profitability in 2010.
Mr McGill joins EUSA from Wyeth Pharmaceuticals, where he held theposition of Vice President and Global Manager for the company'stransplantation business. Previously, he was the Head of Novartis'Transplantation, Immunology and Infectious Diseases Business Unit in Canada,and was a Global Brand Director at Novartis' headquarters in Switzerland. Healso held a number of sales and marketing positions of increasing seniorityat Novartis and Roche in the UK. Mr McGill holds a BSc in Biochemistry fromRoyal Holloway College, London University.
"We are delighted to welcome Iain to EUSA at such an exciting time in thecompany's development," said Bryan Morton, EUSA Pharma's President and ChiefExecutive Officer. "Since founding EUSA four years ago, we have madetremendous progress, raising over $300 million in investment funding,establishing a portfolio of eight marketed and four pipeline products, andbuilding a strong commercialization platform on both sides of the Atlantic.Iain's leadership skills, and track record of growing specialistpharmaceutical businesses, will prove invaluable as we complete EUSA'stransition from a development-stage company to a world leader in its field."
Commenting on his appointment, Iain McGill, EUSA Pharma's President,Europe and International, said, "Having seen the team at EUSA build a greatcompany in a very short period of time, I am delighted to join them as wedrive the business to the next level. With an infrastructure now in placethat can rival even our biggest competitors, EUSA is well positioned tocontinue its rapid development. I welcome the opportunity to contribute tothat progress, as we focus on aggressive organic growth and further productin-licensing and acquisition."
About EUSA Pharma
EUSA Pharma is a rapidly growing transatlantic specialty pharmaceuticalcompany focused on in-licensing, developing and marketing late-stageoncology, pain control and critical care products. The company currently haseight marketed products, including Caphosol(R) for the treatment of oralmucositis, a common and debilitating side-effect of radiation therapy andhigh dose chemotherapy, Erwinase(R) and Kidrolase(R) for the treatment ofacute lymphoblastic leukemia, Collatamp(R) G, a surgical implant impregnatedwith the antibiotic gentamicin, ProstaScint(R) for imaging the extent andspread of prostate cancer and Quadramet(R) for the treatment of pain inpatients whose cancer has spread to the bones. EUSA also has several productsin late-stage development.
Founded in 2006, EUSA Pharma is supported by a consortium of leading lifescience capital investors, comprising Essex Woodlands, 3i, Goldman Sachs,Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest.Since its foundation, the company has raised over $300 million, and completedseveral significant transactions, including the acquisitions of CytogenCorporation, Talisker Pharma Limited, the French biopharmaceutical companyOPi SA and the European antibiotic and pain control business of InnocollPharmaceuticals Inc. Key to its rapid growth strategy is the company'sestablished commercial infrastructure in the US, pan-European presencecovering over 20 countries and wider distribution network in a further 60territories. EUSA Pharma plans to continue its aggressive program ofacquisitions and in-licensing, in line with its ambitious target to becomethe leading specialty company in its areas of therapeutic and geographicfocus.OXFORD, England and LANGHORNE, Pennsylvania, March 8, 2010 /PRNewswire/-- - EUSA Presence Established in Over 80 Countries - Company Positioned for Strong Growth and Profitability in 2010
SOURCE EUSA Pharma Inc